Skip to main content

CORRECTION article

Front. Neurol.
Sec. Epilepsy
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1509148

Corrigendum: A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome

Provisionally accepted
Zubeda B. Sheikh Zubeda B. Sheikh 1,2*Lawrence J. Hirsch Lawrence J. Hirsch 2
  • 1 School of Medicine, West Virginia University, Morgantown, United States
  • 2 Yale University, New Haven, Connecticut, United States

This article is a correction to:

  1. A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome

    1. Read original article

The final, formatted version of the article will be published soon.

    Corrigendum: A Practical Approach to In-hospital Management of NORSE/FIRES Zubeda Sheikh MD, MSCTS1,2, Lawrence J Hirsch MD2 1. Department of Neurology, West Virginia University School of Medicine, Morgantown, WV 2. Epilepsy Division, Department of Neurology, Yale School of Medicine, New Haven CT * Correspondence: zubeda.sheikh@vcuhealth.org Keywords: same as original article Corrigendum on: Sheikh, Z., & Hirsch, L. J. (2023). A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome. Frontiers in Neurology, 14, 1150496. Error in Figure/Table In the published article, there was an error in Figure 1: Flow diagram for evaluation and management of NORSE/FIRES as published. The dose of IVIG was listed as 2 mg/kg over 2-5 days, when it should be 2 g/kg over 2-5 days. The corrected Figure 1: and its caption Flow diagram for evaluation and management of NORSE/FIRES appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

    Keywords: NORSE (New onset refractory status epilepticus), FIRES (Febrile infection epilepsy-related syndrome), Anakinra (PubChem CID: 90470007), tocilizumab (IL-6 inhibitor), rituximab, Super-refractory status epilepticus (SRSE), Neuroinflammation, autoimmune encephalitis (AE)

    Received: 10 Oct 2024; Accepted: 15 Oct 2024.

    Copyright: © 2024 Sheikh and Hirsch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zubeda B. Sheikh, School of Medicine, West Virginia University, Morgantown, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.